Acasă › Leucemie mieloasă acută › Michigan

Studii clinice pentru Leucemie mieloasă acută în Michigan

24 studii pentru Leucemie mieloasă acută caută participanți în Michigan.

Orașe în Michigan

Text oficial al studiului (în engleză)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
și încă 3

În curs de recrutareFaza 2

Vârste de 60 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
și încă 68

În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți

Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
și încă 6

În curs de recrutareFaza 2

Vârste de la 18 la 59 · Toate sexele · Actualizat 28 sept. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Henry Ford Health System, Detroit
Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
și încă 14

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor

În curs de recrutareFaza 1

Până la vârsta de 21 · Toate sexele · Actualizat 23 sept. 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
și încă 6

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
și încă 11

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
și încă 9

În curs de recrutareFaza 2

Vârste de la 18 la 59 · Toate sexele · Actualizat 22 sept. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo
și încă 1

În curs de recrutareFaza 3

6 Months – 21 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT04293562

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

START Midwest, Grand Rapids

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo

În curs de recrutareFaza 3

Vârste de la 1 la 25 · Toate sexele · Actualizat 4 sept. 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
și încă 2

În curs de recrutareFaza 1/2

Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

C.S. Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit

În curs de recrutareFaza 3

29 Days – 21 Years · Toate sexele · Actualizat 24 aug. 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

University of Michigan, Ann Arbor
Wayne State University School of Medicine, Detroit

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Karmanos Cancer Institute, Detroit
Henry Ford Cancer Institute, Detroit

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT06001788

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

START Midwest, Grand Rapids

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 7 aug. 2026 · NCT07751991

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Henry Ford Cancer Institute, Detroit

În curs de recrutareFaza 3

Vârste de la 18 la 75 · Toate sexele · Actualizat 17 iul. 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of Michigan, Ann Arbor
Children's Hospital of Michigan, Detroit
Henry Ford Health System, Detroit
și încă 2

În curs de recrutareStudiu observațional

Toate vârstele · Toate sexele · Actualizat 6 iul. 2026 · NCT01351545

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

University of Michigan, Ann Arbor

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 15 iun. 2026 · NCT05768932

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

În curs de recrutareStudiu observațional

Vârste de 18 ani și peste · Toate sexele · Actualizat 7 mai 2026 · NCT02269592

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Karmanos Cancer Institute, Detroit

În curs de recrutareFaza 2

Vârste de la 18 la 66 · Toate sexele · Actualizat 17 mar. 2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

University of Michigan Comprehensive Cancer Center, Ann Arbor
Karmanos Cancer Institute, Detroit

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 13 mar. 2026 · NCT05735184

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

În curs de recrutareStudiu observațional

Vârste de la 12 la 80 · Toate sexele · Actualizat 28 aug. 2025 · NCT07145411

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.